RG6496

Phase 1Small molecule

Roche

RG6496 is one of 2 small molecule programs targeting Huntington's Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Huntington's DiseaseRecruiting

Huntington's DiseasePhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Huntington's Disease

#DrugCompanyPhaseTrials

Ingrezza

Neurocrine Biosciences

RG6496

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Recruiting

Huntington's Disease

NCT07246941

Clinical

Trials by Indication[1]

Huntington's Disease1 trial

A Phase I, 2-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-ascending Doses of Intrathecally Administered RG6496 in a Randomized, Placebo-controlled, Investigator/Participant-blind Study With an Open-label Extension in Huntington's Disease Gene Expansion Carriers

Recruiting· Roche logo

Roche·Phase 1·NCT07246941·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RG6496. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RG6496 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RG6496. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Roche

RG6496

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Huntington's Disease1 trial

References

Drug Info

Quick Facts

Related News